Conditions: Type 2 Diabetes Mellitus
Keywords: Risk of cardiovascular disease and death in patients with type 2 diabetes mellitus
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 18206
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications

Detailed description:
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes

Arms:
arm 1: None arm 2: Placebo

Interventions: intervention 1: Saxagliptin intervention 2: Placebo
Intervention descriptions: intervention 1: 5 mg or 2.5 mg once daily intervention 2: None

Protocol document: